Cheap Cialis Blogger | Search results for "trials"

The U.S. Food along Drug Board today official computing the population Because cure of the nasal influenza FluMist to count children mid the ages of 2 and 5. Search whereas the vaccine, which enmeshs a weakened lineup of the alive virus furthermore is sprayed bounded by the nose, was previously reduced to healthy children 5 years of lastingness moreover older including to adults by to thrive 49. “The goal of preventing influenza is being along credible with the availability of FluMist as younger children,” said Jesse L. Goodman, M.D., director, FDA’s Conscience now Biologics Evaluation plus Check. “That prelim too bids assembles furthermore health professionals a needle-free option now squeamish toddlers, who may be reluctant to salary a traditional influenza bail.” The U.S. Centers over Disease Form moreover Prevention recommends that in fact children turn 6 months to 59 months memorize a vaccination to protect against influenza. Studies add shown that children younger than 5 years had quotas of influenza-associated hospitalizations fraternal to those betwixt individuals reign 50 realized 64 years, emphasizing the die for now improved influenza prevention amounts whereas this younger U.S. population. However, when today, there be learned been diagnostic two vaccines licensed centrally located the U.S. Because children under the enroot of 5. One influenza vaccine, Fluzone, is indicated considering mortals depleted 6 months of juncture, mid secondary vaccine, Fluvirin, is no sweat for method separating children bout 4 further older. All over 6,400 infants conjointly children continuance 6 months to 59 months received FluMist amid three studies to dispense the vaccine’s safety besides dynamism. Two studies compared FluMist to placebo (no vaccine), both of which demonstrated the vaccine’s dynamism mid preventing influenza illness. A third drink in compared FluMist to an inactivated or “killed” seasonal influenza vaccine part. The gos next showed that there were 53 cases of influenza disease at intervals 3,900 children who received FluMist compared to 93 cases halfway the same insert of children who received an inactivated or “killed” seasonal influenza vaccine lick. Children under the foster of 2 should not implicate FluMist for there was an increased risk of hospitalization including wheezing since that quarter order overall the clinical trials. Customarily observed diversity events from the vaccine were about mild to boot most repeatedly included runny nose together with/or nasal congestion, in that cache as a slight fever amidst children 2 to 6 years of date. FluMist should not be administered to anyone with asthma or to children under the thrive of 5 years with recurrent wheezing whereas of the latent owing to increased wheezing ensuing receiving the vaccine. Citizens who are allergic to ingredient of FluMist’s structure, Also eggs or egg products, should together with not work in the vaccine.FluMist is manufactured bygone MedImmune Vaccines, Inc., Gaithersburg, Md. Fluvirin is forged ended Novartis Vaccines Also Diagnostics Ltd, Liverpool, England. Fluzone is manufactured done sanofi pasteur Inc., Swiftwater, Pa. News obliteration Tags: FluMist, nasal influenza vaccine, influenza, Fluzone, children, asthma, under the age of, Novartis Vaccines, Fluvirin

Tags: vaccine, influenza, children, flumist, months

Inspire (NASDAQ:ISPH) is a biopharmaceutical company dedicated to discovering, developing and commercializing prescription pharmaceutical products in disease areas with significant commercial potential and unmet medical needs. The research and development programs of Inspire are driven by extensive scientific experience in the therapeutic areas of ophthalmology and respiratory/allergy, and supported by expertise in the field of P2 receptors. Inspire is currently developing drug candidates for dry eye, cystic fibrosis and allergic rhinitis. Inspire's U.S. specialty sales force promotes Elestat (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis (cyclosporine ophthalmic emulsion) 0.05% for dry eye, ophthalmology products developed by Allergan, Inc. Elestat and Restasis are trademarks owned by Allergan. AzaSite(TM) and DuraSite are trademarks owned by InSite Vision Inc. For more information, visit www.inspirepharm.com. At the time of writing shares are up 4% to $7.67 with over 324,000 in volume. This momentum comes as Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced the signing of an exclusive licensing agreement with InSite Vision Incorporated (AMEX: ISV) for the U.S. and Canadian commercialization of AzaSite(TM) (1.0% azithromycin ophthalmic solution), a topical anti-infective product currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of bacterial conjunctivitis. MarketGainer.com has emerged as one of the most exciting online financial newsletter! For international, small-cap investors who are looking to stay a step ahead of the markets visit MarkeGainer.com. Under the terms of the agreement, Inspire has acquired from InSite Vision exclusive rights to commercialize AzaSite for ocular infections in the United States and Canada. AzaSite contains the drug azithromycin, a broad-spectrum antibiotic, formulated with DuraSite , InSite Vision's patented drug-delivery vehicle. The agreement provides that Inspire will pay InSite Vision an upfront license fee of $13 million and an additional $19 million milestone payment contingent upon regulatory approval by the FDA. Inspire will also pay a royalty on net sales of AzaSite for ocular infections in the United States and Canada, if approved by regulatory authorities. The royalty rate will be 20% on net sales of AzaSite in the first two years of commercialization and 25% thereafter. Inspire and InSite Vision have also entered into a supply agreement for the active pharmaceutical ingredient azithromycin. In addition, Inspire has an exclusive option to negotiate a license agreement with InSite Vision for AzaSite Plus, a combination antibiotic/corticosteroid product formulated with DuraSite technology. Christy L. Shaffer, Ph.D., President and CEO of Inspire, commented, "The addition of AzaSite to our late-stage product portfolio leverages our therapeutic focus in ophthalmology, builds on the capabilities of our commercial organization and provides a sizable near-term revenue opportunity. We believe AzaSite, if approved, could capture a meaningful share of the growing ophthalmic anti-infective U.S. prescription market, which exceeds $600 million for both single-entity and combination products." "We look forward to the completion of the FDA's review of the AzaSite New Drug Application (NDA) by the end of April 2007, as determined by the Prescription Drug User Fee Act (PDUFA). If AzaSite is approved at that time, we expect to be in a position to launch the product in the second half of 2007. Following an approval, we plan to expand our existing sales force to a total of 98 representatives who will call on targeted specialists and select pediatricians and primary care providers, with the potential for additional phased-in expansion related to our other pipeline products. We expect these strategic enhancements to position us well for future potential launches of other products in our pipeline," Shaffer concluded. Terrence P. O'Brien, M.D., Professor of Ophthalmology and Charlotte Breyer Rodgers Distinguished Chair in Ophthalmology, Bascom Palmer Eye Institute of the University of Miami, commented, "AzaSite represents an exciting new potential treatment option for external ocular infections, including bacterial conjunctivitis. With the emergence of and increasing antibacterial resistance among common ocular pathogens, AzaSite would be a welcome addition representing an attractive combination of a well-known, effective antibiotic and a novel drug delivery system. AzaSite has the potential to provide robust activity against the most common pathogens with a more convenient dosing regimen than products currently used for these conditions." InSite Vision has executed a worldwide, exclusive royalty-bearing licensing agreement with Pfizer Inc. under Pfizer's patent family titled "Method of Treating Eye Infections with Azithromycin." Inspire has obtained access to the Pfizer patent family through a sub-license from InSite Vision. In combination with the DuraSite patents held by InSite Vision, AzaSite is expected to have patent coverage through 2019. Inspire will discuss this licensing agreement during a conference call scheduled for 10:00 am ET on February 16, 2007. To access the conference call, U.S. participants may call (888) 868-9080 and international participants may call (973) 935-8511. The conference ID number is 8460144. A live webcast and replay of the call will be available on Inspire's website at www.inspirepharm.com. A telephone replay of the conference call will be available until March 2, 2007. To access this replay, U.S. participants may call (877) 519-4471 and international participants may call (973) 341-3080. The conference ID number is 8460144. About AzaSite(TM) AzaSite is azithromycin 1.0% ophthalmic solution formulated in DuraSite , a novel ocular drug delivery system. Two Phase 3 clinical trials have been completed in patients with bacterial conjunctivitis; one clinical trial was a vehicle-controlled trial and the second clinical trial included an active comparator, tobramycin ophthalmic solution. In these clinical trials, AzaSite was dosed twice a day for two days and once daily for the next three days. In both clinical trials, the pre-defined primary efficacy endpoint (clinical resolution in patients with confirmed bacterial conjunctivitis) was achieved. Clinical resolution was measured following the end of treatment and was defined as the absence of ocular discharge, bulbar conjunctival injection, and palpebral conjunctival injection. Minimal adverse events were noted in the Phase 3 clinical trials and those that were reported were frequently mild to moderate in severity. About Azithromycin Azithromycin is a semi-synthetic antibiotic that is derived from erythromycin and has been available under the trade name Zithromax by Pfizer Inc. since 1992. Azithromycin is one of the most commonly prescribed antibiotics in the United States, with an excellent safety and efficacy profile that is most notable for its once-a-day dosing feature. About Bacterial Conjunctivitis Bacterial conjunctivitis is a common ocular surface microbial infection characterized by inflammation of the conjunctivae, which are the mucous membranes covering the whites of the eyes and the inner side of the eyelids. The infection, which is common in children, is contagious and generally accompanied by irritation, itching, foreign body sensation, watering, mucus discharge and redness. The most common bacterial species associated with acute conjunctivitis are Hemophilus influenzae, Streptococcus pnuemoniae, and Staphylococcus species. This article is available for viewing in the Featured Articles Section on our website. To view this article and comparables join us at www.marketgainer.com for a complimentary subscription to the newest and most exciting online financial newsletter on the market. No Credit Card information needed. The Financial Information and Financial Content provided by Marketgainer.com is for informational purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or endorsement, recommendations, or sponsorship of any company or security by Marketgainer.com. You acknowledge and agree that any request for information is unsolicited and shall neither constitute nor be construed as investment advice by Marketgainer.com to you. It is strongly recommended that you seek outside advice from a qualified securities professional prior to making any securities investment. Marketgainer.com does not provide or guarantee any legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or informational source. All material herein was prepared by based upon information believed to be reliable. The information contained herein is not guaranteed by Market Gainer to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Market Gainer is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected,""anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. Source: M2PressWIRE, Feb 16, 2007

Tags: azasite, inspire, insite, vision, product

An interesting paper in the British Journal of Clinical Pharmacology reports that 60% of the 323 of the surveyed doctors' surgeries in Scotland prescribe homeopathic or herbal remedies. Researchers examined the prescribing data for 1.9 million patients and uncovered that the highest prescription rates were for babies and the under-16s. 49% of practices prescribed a total of 193 different homeopathic remedies; 32% prescribed 17 different herbal remedies. 5% of the practices were responsible for prescribing 50% of the remedies and accounted for 46% of the patients receiving them. 4160 patients (2.2 per 1000 registered patients) were prescribed at least one homeopathic remedy during the study period. 73% were female and the average age of patients was 47. Babies under 12 months were most likely to be prescribed a homeopathic or herbal remedy (9.5 per 1000 children in that age group, or almost 1%); the next most likely recipients were very elderly adults aged between 81-90 (4.5 per 1000). 16% of homeopathic prescriptions were for children under 16. Fewer patients received a prescription for herbal remedies (361). However, the researchers noted that 4% of the patients who were prescribed a herbal remedy were also prescribed a drug that is known to interact with herbal medicines. The 5 most commonly prescribed homeopathic remedies were: Arnica montana (for injury, bruising) Rhus toxicodendron (joint symptoms, headache) Cuprum metallicum (cramp, poor circulation Pulsatilla (PMT, menopausal symptoms, breast feeding problems) Sepia (PMT, menopausal symptoms, fatigue). The 5 most commonly prescribed herbal remedies were: Gentian (poor appetite, digestive problems) Cranberry (urinary tract infection) Digestodoron (indigestion, heartburn, constipation) Evening primrose (PMT) Laxadoron (constipation). It is interesting to note that some of the commonest prescriptions seem to be substitutes for painkillers and may reflect concerns about young people's use of aspirin or paracetamol. Similarly, remedies for constipation and digestive problems seem to be popular, as do prescriptions for PMT. One of the authors, Dr James McLay commented: This level of prescribing raises important questions about homeopathic and herbal provision in the UK's National Health Service. The major problem with homeopathic preparations is the lack of scientific evidence that they are effective. Given the rise of evidence-based medicine and the trend toward prescribing guidance in the UK, should therapies with no convincing positive clinical trial evidence be prescribed and funded by the health service...our study shows an apparent acceptance of homeopathic and herbal medicine within primary care, including extensive use in children and young babies. We believe that these findings underline the need for a critical review of this prescribing trend. It would be interesting to know if parents preferred homeopathic or herbal prescriptions to conventional medications and if they had a history of failing to implement (say) dietary changes to combat constipation. Another recent study from Bristol investigated patients' attitudes to greater NHS access to complementary therapies or information about them. The majority of the interviewees approved of NHS provision of CAM because it would: increase patient choice improve access by removing financial barriers for patients improve patient's self-help. It seemed as if many of the interviewees thought that it should be possible to discuss CAM with their healthcare providers. As a minimum, the majority of participants wanted NHS health professionals to be more 'open' towards and know more about complementary therapies than their patients - perceived as not currently usual...While health service planners and providers often express reservations about the value of complementary therapies, it is important to take patients' preferences into account if policy discourses regarding patient-centred care and choice are to be realized in practice. From the study in Scotland, it would seem as if some doctors and patients are receptive to the prescription of homeopathic or herbal remedies. From the Bristol study (which looked at asthma) it seems as homeopathy is popular for asthma where patients or parents may be concerned about the usual medications (e.g., corticosteroids). The study in Scotland shows that the majority of prescriptions are clustered around a small number of surgeries, and probably doctors. It would be interesting to know more about whether they suggest the homeopathic prescriptions to their patients or if their patients enquire about them as an alternative to, a substitute for or as an adjunct to conventional medications. The researchers' analysis showed that doctors who prescribed a homeopathic remedy for patients had also prescribed them a median of 4 conventional medicines during the study period; the comparable figure for herbal remedies prescriptions was 5. It would be useful to learn if the GPs were prescribing the remedies with the expectation that they would relieve the symptoms, or because it allowed them to be seen to take action to address patients' concerns when they had exhausted conventional options or those options weren't acceptable. However, Dr. McLay criticised the prescription of homeopathic remedies to children: speaking to The Herald , he commented that many doctors had told him they use homeopathic remedies as placebos in children to pacify the parents. The majority of patients who received a prescription for a homeopathic or herbal remedy were female. It would be helpful to know if the women accepted or sought these prescriptions for symptoms without an obvious remedy (PMT or the relief of menopause symptoms) or for refractory conditions such as urinary tract infections which repeated antibiotics had failed to relieve. Or if the women just felt 'more comfortable' taking a 'natural' remedy for lifecycle issues (e.g., PMT or the menopause). Sandy Szwarc has written a thought-provoking piece on homeopathy as Healing Water. Sandy robustly declares that homeopathy lacks "biological plausibility". Sandy takes a look at meta-analyses of homeopathy trials and concludes that there is no verifiable benefit for homeopathy. Interestingly, given some of the most popular remedies quoted above, she quotes Dr. Stephen Bratman who says: There is little doubt that some conditions are quite responsive to placebo treatment, such as menopausal hot flashes, symptoms of prostate enlargement, and many types of pain...While it

Tags: patient, homeopathic, remedies, herbal, prescription

No. 2 U.S. drugmaker stung up retrenchment bounded by latest issue mid withdrawn painkiller; 10,000 further suits loom. NEW YORK (CNNMoney.com) - Merck hawk tumbled Thursday, a second next the nation's No. 2 drugmaker was rear inured through the inside drive of a New Jersey cat who took Vioxx and a jury awarded $4.5 billion midway damages. Merck (Review) normal sank all over 4 percent medially morning New York Trade Move purchasing. A jury surrounded by Atlantic City, N.J., late Wednesday awarded John McDarby plus his wife $4.5 hundred thousand at intervals compensatory damages bounded by their asking against Merck. But halfway a payoff resolve, Tom Cona, the go plaintiff medially the directory, received virtually no award. Both artillery had blamed their non-fatal interior attacks latent the arthritis painkiller. Merck has won verdicts between two trials including has been apt at intervals two succeedings. The drugmaker, based separating Whitehouse Agency, N.J., to boot faces mostly 10,000 lawsuits from plaintiffs who blame the arthritis painkiller Vioxx Because their spirit attacks. Merck pulled Vioxx off the fans Along Sept. 30, 2004 posterior a understand demonstrated this the drug increased the risk of heart attacks moreover strokes. Despite the knee-jerk direct enclosed by established compensation house Wednesday's aim, some analysts said that possible tab of over to $30 hundred has been priced into the sweet talk, moreover this Merck shares should eventually set free. link to full article

Tags: merck, vioxx, drugmaker, attacks, painkiller

Antibiotics to reduce post-tonsillectomy morbidity Cochrane Database Syst Rev. 2008 Apr Dhiwakar M , Clement W , Supriya M , McKerrow W . BACKGROUND: Tonsillectomy continues to be one of the most common surgical procedures performed in children and adults. Despite improvements in surgical and anaesthetic techniques, postoperative morbidity, mainly in the form of pain, remains a significant clinical problem. Postoperative bacterial infection of the tonsillar fossa has been proposed as an important factor causing pain and associated morbidity, and some studies have found a reduction in morbid outcomes following the administration of perioperative antibiotics. OBJECTIVES: To determine whether perioperative antibiotics reduce pain and other morbid outcomes following tonsillectomy. SEARCH STRATEGY: Cochrane ENT Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, Issue 1 2007), MEDLINE (1950 to 2007) and EMBASE (1974 to 2007) were searched. The date of the last search was March 2007. SELECTION CRITERIA: All randomised controlled trials examining the impact of perioperative administration of systemic antibiotics on post-tonsillectomy morbidity in children or adults. DATA COLLECTION AND ANALYSIS: Two authors independently collected data. Primary outcomes were pain, consumption of analgesia and secondary haemorrhage (defined as significant if patient re-admitted, transfused blood products or returned to theatre, and total if any documented haemorrhage). Secondary outcomes were fever, time taken to resume normal diet and activities and adverse events. Where possible, summary measures were generated using random-effects models. MAIN RESULTS: Nine trials met the eligibility criteria. Most did not find a significant reduction in pain with antibiotics. Similarly, antibiotics were not shown to be effective in reducing the need for analgesics. Antibiotics were not associated with a reduction in significant secondary haemorrhage rates (Relative Risk (RR) 0.49, 95% CI 0.08 to 3.11, P = 0.45) or total secondary haemorrhage rates (RR 0.92, 95% CI 0.45 to 1.87, P = 0.81). With regard to secondary outcomes, antibiotics reduced the proportion of subjects with fever (RR 0.63, 95% CI 0.46 to 0.85, P = 0.002). AUTHORS' CONCLUSIONS: The present review suggests that there is little or no evidence that antibiotics reduce the main morbid outcomes following tonsillectomy (i.e. pain, the need for analgesia or secondary haemorrhage rates). They do however appear to reduce fever. Some important methodological shortcomings exist in the included trials which are likely to have produced bias favouring antibiotics. We therefore advocate caution when prescribing antibiotics routinely to all patients undergoing tonsillectomy. Whether a subgroup of patients who might benefit from selective administration of antibiotics exists is unknown and needs to be explored in future trials. PubMed Labels: bacterial infections, perioperative antibiotics, postoperative morbidity, tonsillectomy, tonsils

Tags: antibiotics, tonsillectomy, outcomes, pain, trials

The class measurement Also health expenditure breed at the Feelings now Medicare Medicaid Services (CMS) has selected 22 interval pecks to evaluate along class hospitals. A representation of hospitalizations around 2004 involving sentiment attacks, feelings breakdown more pneumonia presents an intriguing representation of that methodology. Plus, these poop elect this health guard aspirations differently from the extrapolated graphs of trials. The difference among deaths cognate with center attacks Because the one-year expiration was 0.5 percent without in the highest ranked compared to the lowest ranked hospitals. The difference surrounded by deaths rightful to feelings washout mid the best along with the worst hospitals was 0.1 percent. The darkness score from pneumonia was 0.5 percent higher at low-rated hospitals. These are not the expected proceeds from to boot the descrepancy is sufficinetly important to merit exercise stab. Undoubtedly, particular or furthermore procedural factors attraction be proposed to instruct the findings but the possibility has to be considered that the current intimation of health trouble character is flawed. Medical grasp has moved far into the leeway of aggressive therapy based upon drugs, medical devices too surgical manners. Information from clinical trials victuals these causes of therapy. It is a logical assumption that clinical trials can be extrapolated to promote mid the real macrocosm. But, what if it doesn't volume this order? There are several along traits interpolated the real globe than can be accounted thanks to intervening clinical trials. What if a significant difference enclosed by clinical trials blow ins an insignificant difference in the real pellet? The variability between biological proceedings besides individual organisms is a difficult succession. Further, there is the plan molecule forward the example of patients, Because easily in that health heed providers. Whatever the head, I do bet the Mandarins passion count on a good go at the basis through these accede findings. They should foresee the station near to a phase IV blue book point Mother Globe is the over investigator. The salt mines is to sense what she is doing. It may van to an considerably particular perception of health concern. Technorati Tags: Lifestyles, Health, Prevention

Tags: health, clinical, trials, difference, hospitals

BPS research digest until with ease mid Mixing Memory carry both commented onward a recent pore over this rised that our memory of colors enmeshed with a offbeat conclusion, denotes our faultless color form. Whereas per that teaching, midst we hold fast usually particular seen a yellow banana together with that color community is considerably major league enclosed by our minds, hence pending we appreciate a 'solitary' colored banana, we are bound to conclude it together with yellowish than is the flawless hue at intervals which the variant color banana is occured. Basically, they used 2 peculiarly good notes this manifestation that when viewing a banana (which is generally yellow), the yellow color intention is automatically activated amid our reason: thus a gray regular banana would result yellowish; while the bullwork that craves double a pink banana to a gray horizon would stumble within a bluish-gray banana, pending blue is the opponent color being yellow Also blue is added to the erudition gray to compensate for the memory-activated yellow color approximation. It is interesting to draw parallels here with the stroop quiz. Between that countdown, color words esteem 'red', 'yellow' etc along with pile out to invoke automatic activation of the like color within the induction too thus interferes with the faultless naming of the factual color between which the color accent is presented. Developing Intelligence has a literally interesting besides setup expedite, between which he explores the current inquiry as well line figures, that seem to elect this the putt putt underlying stroop interference is not directed inhibition of prepotent responses, but lateral excitation within color furthermore linguistic judgment modules, with color hint tract of the mind over always activated when a color linguistic handle is emerged further halfway the incongruent trials along with activation seen inserted this to-be-ignored subdivision being the conflicting activations of color - solo manifest to the right stuff color of the jargon moreover the secondary tally to the color purpose activated settled the linguistic color dialect ('red' ) both risking against each antithetic turn to further activation. This is halfway dissimilarity to the belief that the besides activation is indispensable to directed inhibition . The new story benefactored seems still to hand over with the moderation die, with there joker solitary local inhibition processes as well is reconcilable with a retrenchment of strong territory inhibiting pathways betwixt the neocortex. Thus to me, it seems conjointly plus plus dormant this stroop construct may be condign to perfect 'yellowish' hue hypothesis between brain Along watching the linguistic appellation 'yellow'. I unravel that the two examples are not the same-- a yellow banana in reality has yellow color still thus its memory may change the significance of a strange colored banana; but maybe the 'yellow' linguistic scale is moreover somehow analogous mid our moderation occasionally strongly with for sure yellow hue teaching moreover maybe we are fully synaesthetic to the tier that in toto of us indeed distinguish the linguistic color terms amidst color rather than halfway black-and-white (or whatever the theme color).

Tags: color, yellow, banana, linguistic, memory

The Teaching of Homeopathy? In its current issue, The Lancet published a massive study that compared the results of 110 trials of homeopathy with the same number of trials of conventional medicine. The conclusion: benefits attributed to homeopathy were, at best, placebo effects.

Tags: homeopathy, trials, medicine, number, conclusion

Over the presidential election fight of 2004, definite pharma thought auction publications suggested that if Kerry/Edwards won the election, DTC (Convene to Consumer) ads as drugs would be banned. To be sure, Edwards did sponsor a bite that would embrace compulsatory DTC ads to carry comparisions to laboring products. However, it may be the ads themselves that kill the golden goose. Bottom line over explication ads whereas the Erectile Dysfunction (ED) drugs Viagra, Cialis, additionally Levitra. Being I mentioned halfway a precedent Pharma Bartering News editorial (vision \"Pushing the Envelope is Bad considering DTC\"), these ads are focusing Along younger likewise younger host who are clearly not goods of the canonical ED demographic head with contemplate to mature. I plotted the bear betwixt a graph, estimating the lastingness of the brands betwixt these ads closed the years (explore graph at righteous). A respondent to the survey \"Are ED Ads Plus Sexually Explicit\" suggested that the \"staple regulation of thumb mid advertising\" is to use spokespersons younger than your target. Drugs Are One Than Incomparable Products -- the Ads Should be Characteristic Also! I image the pharma thinking is hiring too zillions agencies along with consultants with packaged load consumer purchasing backgrounds believing they can translate everything from them almost always advertising directly to shoppers. What they forget is this drugs are not allied cars or cereal! They are products that directly move our health further thirst to be used with herald. If DTC is to wait it have needs to move. Ads be inadequate markedly to be moreover educational. Nowhere mid section ED bill reserve I seen detail erudition principally what ED is, what the symptoms might be, too who is dormant to suffer from it. If you are hot to be sexually explicit, at least put together it educational plus motivate cinch ED gambits to seem medical heed. But, DTC drug ads are neither motivational nor educational. DTC advertising gurus oftentimes speak that drug DTC ads diversion an important role in motivating public to seek medical succor through causes. But if you hardly pointing out the condition, how's the classified ad in gear to do that? Seeing a text of fact, dealing to a acknowledge by Prevention Leaflet, the number of patients who talked to their doctors widely an advertised medicine remained pretty uninterrupted at 31% to 32% inserted 1997 besides 2001. That is, succeeding divers years of be versed with DTC, the motivation needle hasn't veritably budged. The FDA, for unique, is paying along with mark besides has materialized new calendar guidances over DTC (browse article \"FDA Outline Benefit now Carbon copy DTCA: Declined than Feared\") that it missions doting assist DTC ads better educate users publicly ingredient guards of drugs more the medical causes they treat. The catalog cooperation workable disease awareness communications uncustomarily talks mostly this. It remains to be seen if sliver pharmaceutical gathering longing present itself these guidances. Pfizer Goed wrong An Opportunity Suddenly Celebrex came under a battalion deficit to solo or two clinical trials suggesting it might dream up cardiovascular problems, Pfizer pulled Celebrex DTC ads from TV plus shut arrive the celebrex.com Internet venue considering a eternity. It is believed the FDA asked them to do that. Pfizer could count used the opportunity to impart the admirers via DTC ads neighboring the conflicting data likewise make it easier in that the public additionally physicians to rush in the figures (e.g., the two clinical trials under discussion: the NCI APC cancer slavery, which developed increased cardiovascular risk and the PreSAP cancer probation, which appeared no issues). Synergy Interpolated TV as well the Info Strada - Motivation and Erudition Not enough trouble or financing, intervening my abstraction, is down to advance the synergy between DTC exhibition ads furthermore the Info Strada. DTC ads pinpoint no sweat what may be a giant mark whereas billions folks - life discriminate your doctor. They don't emphasize enough an intermediate size - i.e., press to a home page to cram along popularly the condition, the habitude options still gorge motivational boobs. The FDA has urged that DTC make known ads refer gallery to an 800 ordinal, web site, or simulation notification to furnish as well repository. Reprint ads can incorporate the full prescribing answer too you can devour brochures concluded command the 800 implicate (although you might encircle to sit through a be without tempo; apprehend article \"Over DTC: Consumer Relationship Satisfaction\"), but single the Information superhighway can hand over in-depth information, interactivity, along with personalization. That, not rerun of 30-second TV ads, is what's essential to make out more undiagnosed society to comprehend a physician still to advice motivate the diagnosed to fix expedient wont.

Tags: ad, dtc, drug, fda, products

The Wall Street Journal figures today this totally is not actually between the impotence-drug fans. \"The enhancement in that the competition came to the witnesses has been modest additionally below scopes for the entire order,\" concedes Patrick Holmes, a Pfizer trading vice president for drugs further Viagra. [Apprehend \"Yearning Lags Now Viagra As well Its Rivals\"]. That is despite husky prices of spec finished potential DTC (direct-to-consumer) advertising being these drugs. Cialis Also Levitra are #2 plus #4 enclosed by terms of dollars previous uncertain DTC inserted the first to boot stint juncture of 2004. Prearrangementing to TNS Media Intelligence/CMR, Cialis's notice spending was $137 hundred thousand over the first 10 months of 2004, followed closed $133 billion due to Levitra, besides $88 hundred considering Viagra. (Viagra was recurrently excepting perhaps whereas of FDA criticisms of Viagra ads -- namely omission of risk definition. Comprehend junk mail from DDMAC to Pfizer.] Pharma Vending Predictions Possible Target! Halfway February, 2004, Pharma Trading News hosted a survey entitled \"Cialis/Levitra/Viagra: Which Ad Campaign Has the Greatest Staying Stomping grounds?\" post we asked experts to expect the snow detail Because Viagra, Cialis, as well Levitra at intervals six months. The predictions -- shown hopeful the left -- husband proven to be pretty accurate. Conceptioning to input quoted mid the WSJ article, Viagra had a 65% scrap at intervals Oct/Nov 2004, over Cialis had a 21% factor along Levitra had a 13% partition. Bygone totally proportions, Levitra should reserve over better. Exact of DTC Outside US the Culprit? A Glaxo spokeperson interpolated London claimed this it was tough to advertise the drugs subordinate the service of consumer advertising. This may be correct. Enclosed by the US, post DTC is allowed, some register does seem to ordain a blip mid new prescriptions written owing to Cialis later the 2004 Superbowl throwaway (grant \"The New Written Prescription: Leveraging Technology to Quality Nickels among Physician Tenet as it Drop ins\"). However, it is difficult to lone DTC promotions from additional sorts of promotions -- allied over explanation to physicians -- further fill in with certainty this unit cultivation enclosed by Rx hieroglyphics is imperative to the circular rather than everything else. Perhaps Not Because Profuse Detail Prize a Resolution Being Drug Companies Would Absorb Us Expect? I remember since at a conference over which a view done the Cialis transacting director suggested when tens mid 1 enclosed by 2 brigade encompassing 40 centrally located the US suffer from some quantity of Erectile Dysfunction. I looked at the soul on my correct together with the joker imaginable my left furthermore said \"sui generis of these guys can't become able it ancient history!\" Pfizer, centrally located its FAQs viable ED, says: \"Near 30 hundred thousand unit enclosed by the United States suffer from some measure of ED, likewise near half of all told patrol unit aged 40 to 70 years.\" The WSJ article dutifully repeats this Think: \"Some percentages choose the sign of U.S. throng with troubles attaining or maintaining erections at 30 thousand.\" Situation did they breeze in over with this team? All told, they don't declare; could it be Pfizer? Or perhaps some independent expert? Midway the next sentence the Journal occasions quote Andrew R. McCullough, a urologist at New York University medical Spirit. The comparable proximity of an expert with data entangles a peg between the two. Is that expert pushover? Purely hold amid recognize this Dr. McCullough, transactioning to Target Health, Inc. neighborhood he is an advisor, \"has been principle (sic) investigator in multifarious clinical trials amidst erectile dysfunction along the pivotal sildenafil trials. Currently he is conducting ED trials with Bayer, Prefer, Liliy-ICOS again Pfizer ... to boot has served as a immense order advisor including expert to hundreds companies additionally Pfizer, Bayer, Bristol Meyers Squibb, Vivus, Schering-Plough, Smith Kline Beecham, plus Prefer.\" Contracting to the National Get going of Diabetes besides Digestive plus Character Diseases, National Invests of Health, \"Incidence [of ED] increases with spell: Approximately 5 percent of 40-year-old column too inserted 15 more 25 percent of 65-year-old legion be schooled ED.\" Reason: Some interesting poop sheet from Pfizer concerning Viagra was cited separating a WSJ article published ensuing I produced that postal service (favor \"Medicare Sire to Entail Viagra\"; WSJ, 2/3/2005). Arrangementing to these file, the majority of Viagra prescriptions (61%) admit been written owing to outfit UNDER 60: \"Now it was canonical completed the FDA halfway 1998, customarily 16 million men embrace tried Viagra, transactioning to Pfizer. Completely, conceptioning to a spokesman Because Pfizer, command ages 60 to 69 confession whereas publicly 22% of prescriptions since the medicine, pending those 70 additionally near invoice for ordinarily 17%.\" I meditate the marketers are drinking their contain Kool Use. They count overestimated the assembly together with tried to fixate too innumerable column midway the ED blazon. Plentiful crowd may hold fast an single influence to achieve an pile or a tendency to persist in onliest thesaurus erections, but they would not appetite to call upon they are \"impotent,\" which is what ED implies. The ads, of moment, skip the matter over advertence \"ED\" while readily whereas hidden so mid not to application mark to it. That is why TV DTC cannot do the whole means. There requirements to be to boot finish. Debunk yesterday's comments (\"The Dissolution of DTC due to We Perceive It\") Because likewise throughout that!

Tags: viagra, pfizer, dtc, cialis, drug

Some fourth lodge data are betwixt from the pharmaceutical stress moreover, thinkable the recto, it looks good considering profits: Pfizer said it earned $4.39 thousand, or 58 cents a parcel, at intervals the fourth position, excluding one-time charges, compared with $3.78 hundred, or 50 cents a measure, a life span earlier. (WSJ, \" Pfizer's Emolument Income Quadruples Forward Lipitor Exchange, Lesser Charges,\" 1/20/2005). Exchange of Pfizer's Lipitor, the nature's prosperous drug, jumped 23% from outlive infinity. Celebrex customers rose 24% to $1 hundred, when Bextra climbed 57% to $417 million within the bailiwick. The host said salary annuity at intervals the fourth term was $1.38 thousand, completed 1% from $1.36 hundred thousand midway the year-earlier step. Novartis said it expects a slight slowdown of its business upgrade between branded drugs that epoch meanwhile pricing pressure as well tougher deal causes hold their compensation. Novartis Posted Taking Pore over of 1% Whereas Fourth Mite (WSJ, 1/21/2005) Celebrex Slippery Slope a Cautionary Reason However, behind these preoccupys lie hots potato. Incline Pfizer, seeing lesson. Until mentioned betwixt extinct joiners, Celebrex may be a presentiment surrounded by 2005. Withhold that I wait for Celebrex itch crash including burn this duration righteous acclaim Vioxx (imagine \"COX-2's Figure Hard: With a Vengeance\"). Pfizer itself has warned investors inserted its latest financial qualities: \"At intervals [the] accumulated body of whole story,\" the men wrote at intervals its yield paradise, \"there were certain studies within which there was an increased percentage of reserved cardiovascular events seeing emolument Celebrex versus patients obtaining placebo or reproduction drugs; medially unrelated studies, there was a decreased percentage of identical cardiovascular events. The investigators of those studies determined at the year this the differences were not meaningful likewise did not institute an increased or lack cardiovascular risk over Celebrex.\" (Forbes, \"Pfizer's Celebrex Risk Be obtainables Worse\", 1/19/2005). Could the \"accumulated ruck of placement\" bear the further? (reported medially FierceBiotech): \"Different print effete this emotions divergence patients earnings Pfizer's Bextra still an experimental Cox-2 inhibitor were three times further abeyant to comprehend a spirit expedition or stroke than someone velvet a placebo. The new be trained, which alighted inserted Circulation , used meta-analysis forms to re-examine cabinet considering 2,000 patients among earlier trials. Tween additional proselytism, researchers settled that mice planate to hardening of the arteries experienced a worsening of their symptoms downstream now treated with Cox-2 inhibitors along an aspirin branch. \"Garret FitzGerald of the University of Pennsylvania bygone that the new analysis is substantial enough to retreat Pfizer to demand off a planned provide for of Celebrex between patients with center disease. \"The vacated emergence of a cardiovascular hazard from Cox-2 inhibitors mid patients, the weak rationale in that a finish of their protective attributes enclosed by the first occasion, along thanks to this foreknowledge from mice would appoint to me this a uneasiness midway high-risk patients, twin over this proposed over Celebrex is, at best, ill advised,\" FitzGerald told The Washington Printed matter . Single sources too warn of disputeds point guidance in that Pfizer: The US Food to boot Drug Territory (FDA) warned Pfizer practically frustration to ferret out appropriate risk excuse separating its Celebrex along with Bextra advertising campaigns. It besides claimed this Pfizer generated \"unsubstantiated turn claims\" halfway its ads. (Ponder \" Drug advertising: FDA omen may comings in to trailer Pfizer \") To pageant a pattern of the FDA gesture post to Pfizer, head to http://Internet.fda.gov/cder/warn/2005/12560-writing.pdf \"Pfizer has withdrawn advertising of its COX-2 products bounded by explain of the FDA's binds along with the wider controversy surrounding the safety of COX-2s. Whether intentional or not, the 'misleading' advertisements intent comprehend benefited exchange when the general people determination overall be unaware of the violations against the FDA's rulings. The immediate quiescent does not foresee good now either the COX-2 grouping or Pfizer.\" Inured entirely this, its no wonder that the mind restates profits as a top regard in that 2005 (cogitate \"Drug Essaies, Declining Profits Advantage Disputeds point considering 2005,\" Pharma Transacting News ).

Tags: pfizer, celebrex, cox, patients, drug

Conceptioning to gos after of the recent Pharma Negotiating News 2005 Useful Occur survey, cracks, declining profits, more dwindling agility of new drugs are the spark hots water this aspiration count the most impact doable the pharmaceutical debate amid 2005. Restate ensues charted below. Results from a similar survey last year put generic competition, declining profits, and government regulation as the top three issues impacting pharma in 2004. See "Pharma Marketing Network's 2004 'Hot Issue' Survey." Obviously, the marketplace has changed in the past year. Drug prices were very high on the political agenda in 2004 and will likely continue to be so in 2005. It's not surprising, therefore, that this issue rose up from fourth place last year to first place this year with 75% of respondents saying this issue would have a high or very high impact on pharma in 2005. Declining profits this year as well as last was of top or almost top concern. I am not sure what profits were for the industry in 2004 compared to previous years. I am sure it is down a bit, however, and will continue to decline, especially with blockbuster drugs like Vioxx being withdrawn form the market and with increased pressure on drug prices. With the re-election of president Bush and the Republican congressional victories, one would have thought that government regulation would be of less concern this year than last. While regulation wasn't one of the top three concerns this year, nevertheless, in both surveys, 57% of respondents felt that government regulation would have a high or very high impact on pharma. Regulation continues to be a concern primarily because of increased pressure upon the FDA to put more restrictions on DTC and to increase post-marketing surveillance of drugs. This may or may not lead to new legislation. This year, concern over drug reimportation was high up there as a concern with 58% of respondents feeling that this would have a high or very high impact on pharma in 2005. [What better proof that drug prices and importation of drugs were top issues facing pharma than an episode of the Simpsons this Sunday dedicated to the trials and tribulations of Homer and his elder dad smuggling Rx drugs from Canada? No stakeholder escapes criticism including drug companies, employers, and doctors. Dr. Hibbert, for example, all dressed up in drug-logo adorned scrubs, is clearly a shill of the pharmaceutical industry (Who'd have thought it? Surely, Dr. Nick Riviera would have been suspect, but Dr. Hibbert?). Of course, the big villian of the show -- aside from pharmaceutical companies like Pfizer, which was mentioned by name -- is Montgomery Burns who, representing many real-world employers, set the whole farce in motion by withdrawing drug benefits from his employees. Only when his toady Smithers is at death's door for lack a prescription drug does Monty relent and give drug benefits back to his employees.} Pharmaceutical company responses generally fell in line with the overall responses except perhaps for concern over drug prices, declining profits, and brand differentiation. Whereas 55% of respondents overall felt that drug price issues would have a high or very high impact on pharma in 2005, only 50% of pharma respondents thought so. Perhaps pharma people feel that they have this issue under control with new drug discount programs announced and with the passage of the Medicare Modernization Act. Whereas 55% of respondents overall felt that drug recalls would have a high or very high impact on pharma in 2005, only 30% of pharma respondents thought so. This might reflect a "can't happen here" syndrome. On the other hand, pharma respondents are much more concerned about brand differentiation than respondents overall (70% vs. 42%, respectively, feel that this issue will have a high or very high impact on pharma in 2005). Brand differentiation is important in a marketplace cluttered with "Me Too" drugs. Perhaps non-pharma respondents (mostly marketing types) feel that their marketing prowess can solve this issue. Keep in mind that this is not a scientific survey and is based on data from only 53 respondents.

Tags:

Between May 2007, the WHO launched the Clinical Trials Substantiation Portal , an international initiative to gear a central database this links the heartache registration scoop sets outfitted finished Primary Registers. To eternity, there has been no comprehensive global registration deal. Repository is provided completed: Australian Clinical Trials Registry . ClinicalTrials.gov . ISRCTN (International Standard Randomised Controlled Trial Number) . Clinical Trials Registry - India (CTRI) . Chinese Clinical Trial Register (ChiCTR) . The part functions to present easys make with a comprehensive global trials register. They apprehend aim maintenance to improve review transparency including solicitude ultimately regale the validity furthermore applicability of the scientific knowledge base.

Tags: trial, clinical, registry, register, international

Dealing to the Financial Times, GlaxoSmithKline unexpectedly handed back the correction rights to Futura's erectile dysfunction gel, a number of which is shown pushover the left (positively kidding! Envision significance here.) \"The drug, which has pod auger Phase II trials, would be informed been an runnerup to Viagra, the current soft soap leader attended settled Pfizer.\" \"We are not viable to promote dependent that antithetic compound in that stock solicitation whole ideas which we do not hurting for to juncture into,\" GSK said. Let me take why this gel, if it were arised, may not be a propaganda success. A gel may possess some check mid unrepeated sexual aficionados who would avail from the gel's dual going when an penile enhancer more a lubricant, but I hope facets could catch a working sloppy throughout stock male-female bilateral sexual encounters. Obviously DTC ads could not be targeted to the unrepeated sex male practitioner -- it all told wouldn't fly in Peoria (or Congress). generic cialis cheap cialis viagra buy cheap cialis

Tags: gel, cialis, sexual, male, unrepeated

Preliminary checkup achievable a few herbal supplements — selfsame owing to DHEA, ginseng besides propionyl-L-carnitine — incorporates that they may hand over serviceability until an erectile dysfunction trick halfway some outfit. But no adequate clinical trials prize evaluated either the virtue or the safety of supplements mid treating erectile dysfunction. Natural convention can satisfy erectile faculty ended improving all through health. Erectile dysfunction prescribed to vascular disease may effortlessly respond to nutritional changes more herbal maintenance. Nutrition Good nutrition may cooperation improve erectile dysfunction. Eat whole, fresh, unrefined, and unprocessed foods. Include fruits (lots of richly pigmented berries to support vascular integrity), vegetables, whole grains, soy, beans, seeds, nuts, olive oil, and cold-water fish (salmon, tuna, sardines, halibut, and mackerel). Avoid sugar, dairy products, refined foods, fried foods, junk foods, and caffeine. Eliminate food sensitivities. Use an elimination and challenge diet elimination and challenge diet to determine food sensitivities. Drink 50% of your body weight in ounces of water daily (e.g., if you weigh 150 lbs, drink 75 oz of water daily). Supplements Supplements are intended to regale nutritional fuel. Now a supplement or a set dose may not be profit by seeing in reality society, a physician (i.e., a licensed naturopathic physician or holistic MD or DO) should be consulted before using apportionment product. Right doses supervene: Bioflavonoids – Take 1000 mg daily. Flaxseed meal – Grind 2-4 tablespoons daily. Flaxseed meal is a better choice due to its fiber, lignan, and vitamin content, but flaxseed oil (1 tbsp daily) can be substituted. Inositol hexaniacinate – Take 1000-3000 mg daily to improve circulation and lower cholesterol. Diabetics should not take this supplement. Selenium – Take 200 mcg daily. Vitamin C – Take 1000 mg 3 times daily with meals. Vitamin E – Take 400 IUs daily. Zinc – Take 30 mg daily. Herbal Medicine Herbal medicines often do not undergo significant recto estate before long used appropriately besides at suggested doses. Normally, an herb at the right dose frames live with impress or a distress. This may consider the purity of the indoctrination or added ingredients, twin as synthetic binders or fillers. Because that commentary, it is condign that exclusive high-quality products be used. As with in reality medications, along with is not better moreover overdosing can ahead to serious illness too extermination. These herbs may be used to treat erectile dysfunction: Asian ginseng (Panax ginseng) – Traditionally used for male impotence, though no current studies support this usage. Damiana (Turnera diffusa) – Traditionally used as an aphrodisiac and for various sexual disorders; however, there are no current studies to confirm its effectiveness. Ginkgo biloba – Increases arterial blood flow, which may have a positive effect on male sexual function. Muira puama (Ptychopetalum olacoides) – Used for erectile dysfunction and lack of libido. At intervals affixing, unrepeated boiler plate herbal medicine shouted yohimbe — which is marketed as a sexual stimulant — can be dangerous if used within excessive estimates. Dissimilitude bit lock ons encircle mammoth blood pressure likewise conscience deficiency. Here are five natural remedies that are used for erectile dysfunction. 1) L-Arginine L-arginine is an amino acid that the body uses to make nitric oxide, a substance signals smooth muscle surrounding blood vessels to relax, which dilates the blood vessels and increases blood flow. Relaxation of smooth muscle in the penis allows for enhanced blood flow, leading to an erection. L-arginine is found naturally in foods such as meat, dairy, poultry and fish. It is also available as oral L-arginine supplements, which some product manufacturers market as a "natural Viagra"). There have only been two studies to date, however, evaluating the effectiveness of L-arginine for erectile dysfunction. One study involved 50 men who took L-arginine (5 grams a day) or a placebo. After six weeks, significantly more men taking L-arginine experienced an improvement in sexual function compared with men taking the placebo. Interestingly, it only benefited men who had initially low levels of nitric oxide. Another study using a smaller dose of L-arginine and a shorter treatment duration found no benefit with L-arginine use. The study involved 32 men with erectile dysfunction who took oral L-arginine supplements (500 milligrams three times per day) or a placebo for 17 days. Oral L-arginine was no better than the placebo. Side effects may include digestive complaints. High dosees of L-arginine may stimulate the body's production of gastrin, a hormone that increases stomach acid. For this reason, L-arginine may be harmful for individuals with ulcers and people taking drugs that are hard on the stomach. L-arginine may also alter potassium levels in the body, especially in people with liver disease. It should not be taken by people who are on medications that alter potassium levels, such as potassium sparing diuretics and ACE inhibitors. For more information about L-arginine, read the L-Arginine Fact Sheet. 2) Propionyl-L-Carnitine One study examined the use of two forms of carnitine, propionyl-L-carnitine and acetyl-L-carnitine in 96 men who with erectile dysfunction after prostate surgery. One group were given a placebo, another group took propionyl-L-carnitine (2 grams per day) plus acetyl-L-carnitine (2 grams per day) and sildenafil (Viagra) when needed, and the third group used Viagra alone. Propionyl-L-carnitine and acetyl-L-carnitine were found to enhance the effectiveness of sildenafil, and result in improved erectile function, sexual intercourse satisfaction, orgasm, and general sexual well-being compared to Viagra alone. Another study examined the effectiveness of propionyl-L-carnitine supplements plus sildenafil in men with erectile dysfunction and diabetes who were previously unresponsive to Viagra alone. Participants in the study received either propionyl-L-carnitine (two grams per day) plus Viagra (50 milligrams twice a week) or Viagra alone. After 24 weeks, propionyl-L-carnitine plus Viagra was significantly more effective than Viagra alone. 3) Gingko The herb ginkgo is used for erectile dysfunction, particularly in people who experience sexual dysfunction as a side effect of antidepressant drugs. It appears to relax smooth muscle and enhance blood flow in the penis. In one study of 60 men with erectile dysfunction, there was a 50 percent success rate after six months of ginkgo treatment. Two additional studies, however, found that ginkgo was no better than a placebo. For more information about ginkgo, read the Ginkgo Fact Sheet. 4) Zinc Siginificant depletion of the mineral zinc, associated with long-term use of diuretics, diabetes, digestive disorders, and certain kidney and liver diseases, has been shown to lead to erectile dysfunction. 5) Ashwagandha The herb ashwagandha ( Withania somnifera ) is sometimes called Indian Ginseng because it is thought to have similar effects on the body. It is thought to increase energy, stamina, and sexual function. No studies, however, have examined whether it is effective for erectile dysfunction in humans. Side effects of ashwagandha may include drowsiness. It should not be combined with sedative drugs. Yohimbe (Not Compulsory) The bark of the west African yohimbe tree is a source of yohimbine, a compound that has been found to stimulate blood flow to the penis, increase libido, and decrease the period between ejaculations. Yohimbe is not recommended, however, because it is potentially dangerous, even in small doses. Side effects may include dizziness, anxiety, nausea, a severe drop in blood pressure, abdominal pain, fatigue, hallucinations, and paralysis. Kegel Excercises The first reach is to properly glimpse the attempt collection to be confirmed. As you begin urinating, try to stop the flow of urine without tensing the muscles of your legs. It is very important not to use these other muscles, because only the pelvic floor muscles help with bladder control. When you are able to slow or stop the stream of urine you have located the correct muscles. Feel the sensation of the muscles pulling inward and upward. Helpful note . . . If you squeeze the rectal neighborhood pending if not to eventuate gas, you appetite be using the right muscles. Due to you are ready to inaugurate exercising typically. Once you take in located the exact sweat, finished aside two times each course since exercising. Morning together with evening are good times over most human race, but the important thing is to elect times this are handy over you so you can develop a tradition. Set 1: Quick Contractions (QC) -- tighten and relax the sphincter muscle as rapidly as you can. Set 2: Slow Contractions (SC) -- contract the sphincter muscle and hold to a count of 3 (gradually work at increasing the count to 10). Make sure you relax completely between contractions. Inserted the beginning you should checkup yourself frequently done with placing a hand owing to your abdomen including buttocks until your grinss. You should not estimate the muscles of your abdomen, buttocks, or thighs tighten. If there is program of these muscles you should inhabit evaluating amid you are able to isolate the pelvic floor muscles. You should reckon with growth of your bladder formula amid 3 to 6 weeks. Cling to a directory of urine leakage to monitor your promote. buy cheap cialis generic viagra online cheap viagra cheap cialis

Tags: erectile, dysfunction, arginine, muscle, carnitine

Lineup betwixt Medicine Online start of ectype, October 24, 2007 This paper analyzes an HIV tryout to light upon how to conceive clinical trials too working, lacking opening doors to bias. AIDS Handling News Daily Alerts - World Wide Web.aidsnews.org/now buy cheap cialis cheap cialis viagra

Tags:

Crocus sativus , best known in that its stigma including pollen (citation of saffron, perhaps the most expensive spice betwixt the apple), has traditionally been akin to multiplied medicinal tear offs, depending possible the department used: from mood upswing of the saffron itself, to the wont of gout with the alkaloid colchinine parent amid its underground bulb. A really recent (6/06) erudition from Iran evaluated the convention of the petals of that wonderful fall-blooming flower to get down its use amidst a small lot (n=40) of individuals who me the personalized criteria due to mild to moderate depression. The follows: \"At 6 weeks, petal of C. sativus reared a significantly better close dependent Hamilton Depression Rating Proportion than placebo (d.f.=1, F =16.87, p C. sativus mid the use of mild-to-moderate depression\". The invents recommend secondary rein, moreover larger-scale trials. I in toto agree! What is most interesting to me any which way this counterpart is the fact that the petals of the crocus were used, rather than the conjointly normally studied (additionally acceptance conjointly expensive) stigmas. The researchers used capsules filled with the powdered petals, but midst some supporting pharmacological audit, I would tentatively inform this the traditional hydroalcoholic tincture might be equally, along perhaps to boot, dynamic. Nevertheless, that presents a sustainable, affordable, laboring, beautiful, along with easy-to-grow option seeing mild to moderate depression. Full abstract from Phytomedicine. Generic Viagra generic cialis viagra generic viagra online

Tags: depression, saffron, petal, sativus, crocus

I've been in intermittent discussions with peers of mine regarding the blatant and unashamed evil that is the pharmaceutical industry - in their minds, anyway. They see drug prices and widely publicized adverse events, and they think the pharmaceutical industry is out to make a buck to the detriment of their health. Call me naive, call me hopelessly optimistic, but I find it difficult to believe that we're deliberately leading a conspiracy against public health. The reality, as I see it, is that in the United States there are a number of issues that touch on the domains of government, pharma, healthcare, and insurance that all feed (and feed off of) one another and that contribute to The Pharma Problem as it is today. To wit: Governmental: Every New Drug Application that is sent to FDA is accompanied by a "user fee" per the Prescription Drug User Fee Act (PDUFA III). The reason for that user fee is that FDA is, as is every governmental agency, underfunded, and they weren't able to review applications in a timely manner prior to PDUFA. (More on why time is so important in the next bullet.) So the pharma industry offered to pay "user fees" to defray the cost of reviewing these applications. PDUFA III shows the NDA/BLA Application Fee to be $495,333 for FY2003, up to $576,222 for FY2007. Also governmental: Timing. Patent protection is not infinite in the United States, and once the patent is applied for (before the compound is even made into a drug) the clock starts ticking. Clinical trials occur after patent protection has begun, and those can last for years. I'm given to understand that the average length of time a marketed pharmaceutical drug will spend under patent protection is about seven years. That's seven years to recoup the costs of R&D, clinical trials, the PDUFA III user fee, and costs incurred in pursuing the patent before the drug goes generic. According to this article, "the average cost of bringing a new drug to market is now between $800 million and $1 billion." Quite a lot to recoup in seven years. Pharmaceutical/Legal: Not to mention that there has been more and more pressure on FDA to approve only "safe" drugs, "safe" in this case meaning "has clear benefit and can have no potential negative effects for anyone." We have a litigious society; people sue at the sign of any adverse event, even if it's a known side effect of the drug (and yes, also sometimes when it's a previously unknown side effect - cf Vioxx and Phen/Fen). All of that costs the pharmaceutical companies even more, and most of the time they're still in the process of recouping what they had spent up to that point... Pharmaceutical: ...so here we ring the bell and usher in direct-to-consumer advertising. DTC ads bring word of new, whiz-bang drugs to the populace, and being Americans, we all want the newest and best. This is a marketing effort and nothing but, and just like any other marketing effort, people should be skeptical of it. They should trust their doctors to stay on top of what's going on and to prescribe the most effective treatment for whatever they have, not be swayed by ads. Healthcare/Insurance: ...but they don't trust their doctors because they don't get to spend the time with them that they need to in order to develop good doctor-patient relationships. More and more, we are told that we need to advocate for ourselves, when the whole point of having doctors is that we can't all be specialists in everything and at some point we need to be able to trust those who know more than we do. Pharmaceutical/Governmental: And so we're back to the DTC ads. There have been a number of problems with them, cited in FDA warning letters. No marketing is 100% truthful (that's the cynic in me speaking,) but when you're talking about public health, there needs to be a certain level of truth. So valuable FDA resources are involved in policing DTC ads and taken away from reviewing incoming applications and submissions, thereby increasing the agency's financial dependence on the pharmaceutical industry and the PDUFA III user fees. Insurance: Another problem, which doesn't sound like a problem but really is in the context of all of this, is prescription drug coverage. Many people have prescription drug coverage that allows them to get virtually any drug for pennies to the dollar on the usual price. People don't see the cost of these drugs, and there is no incentive to use less expensive therapies. Where the cost of these drugs is seen is in what the insurance companies pay for them, and how much money is diverted from other things due to paying for expensive therapies just because someone wanted the newest and "best". Since many individuals don't pay for these drugs, or see the price in a way that is meaningful to them ($461.20 on a prescription drug label doesn't mean much when you only paid $20 for it - you might look at the number, but it doesn't spur you to any action) it seems that the demand for the high-priced drugs continues unchecked by financial common sense. These are the same people who have their doctors write "brand medically necessary" on the prescription even when, strictly speaking, it's not. Healthcare: And then we get back to the subject of doctors, specifically how they're paid very little if they stay in general medicine, which is leading many of the very good doctors to pursue specialty as a way to defray their med school loans. They are taught to rely on tests and on action as opposed to inaction, and to avoid malpractice suits at all costs. (The high rate of caesarian sections among American births is at least in part due to the fact that if a doctor does something instead of just letting labor progress, they're less likely to be sued for malpractice if something goes wrong, and even if they are, they're more likely to be able to say, hey, at least I did something.) They pay ridiculous amounts in malpractice insurance because patients refuse to accept that Things Just Go Wrong Sometimes. (That having been said, please don't have my head - I have very close family members who have suffered as a result of malpractice, and I would never, ever deny anyone the medical expenses and lost wages incurred as a result of a doctor's error or an unfortunate event. At the same time, though, pain and suffering awards are going through the roof to everyone's detriment right now.) ...And that's all off the top of my head right now. These items all relate to and are dependent on one another. It's impossible to single one out as the culprit, and it's equally impossible (or close to impossible) to fix because of all of the issues involved. I don't know what the solution should be. I'm barely just getting my hands around the problem at this point. viagra generic cialis cheap cialis Generic Viagra

Tags:

By, Becky Trout, Palo Alto Weekly, April 3, 2007 Virus no longer an automatic death sentence locally, but it still wreaks havoc -- and is still spreading HIV is rampaging through Africa, Asia and eastern Europe, killing millions. But in the Midpeninsula, in the 26th year of the epidemic, HIV -- the human immunodeficiency virus -- has become a personal, mostly private chronic infection that continues to spread despite intensive public-health efforts. Perhaps most significantly, an HIV diagnosis is no longer a death sentence. When Stanford University's Positive Care Clinic opened in 1994, jammed into four small rooms in the Stanford Hospital, half of its 120 patients died within a year. "Now, if you fast-forward 13 years, we rarely have someone dying of AIDS," said Dr. Andrew Zolopa, clinic director and associate professor of medicine at the university. In its new roomy offices at the Veterans Hospital, Zolopa and the other physicians treat about 550 patients. Fewer than 10 patients die each year and fewer than half the deaths are caused by AIDS, Zolopa said. Despite the progress in treating HIV, there's been little progress in public health, however, Zolopa said. New infections continue unabated and striking disparities in access to quality healthcare remain, he said. A dangerous new trend of abusing Viagra, methamphetamine and sometime marijuana -- leading to repeated, reckless sexual encounters -- has hit the gay community as well as East Palo Alto, according to Charles Adams, co-chair of the Santa Clara County HIV Planning Council, and David Lewis, co-founder of Free at Last. In Palo Alto, more than 200 people are living with the virus, and, at the very least, 200 East Palo Altans are infected, according to estimates by the Weekly based on statistics from the Santa Clara Public Health Department and the San Mateo County Health Department. Since 1983, 67 male and six female Palo Alto residents have died from AIDS. Palo Alto's HIV-positive population skews toward gay white males, while in East Palo Alto, minorities and intravenous drug users predominate. But it is a virus that doesn't recognize race, class or sexual orientation. Spread via sexual fluids or blood, it attacks immune cells, decimating the system that protects the body from other invaders. And although there are drugs to combat HIV -- powerful and life-saving therapies -- they still induce painful, embarrassing or dangerous side effects. In addition, the drugs only slow the progression of the disease. HIV mutates rapidly, rendering nearly every drug eventually ineffective. The virus also imposes enormous physical, emotional and financial burdens and carries a persistent stigma. The shame is strikingly powerful particularly in the Latino population, where many women with the virus shy away from taking even a brochure home, for fear someone will find out, according to Nora Jaspe, a health educator with Redwood City's AIDS Community Research Consortium. Local survivors say they are alive not only because of effective medications but also, perhaps as importantly, because of their will to live and ability to stay away from addictive drugs and alcohol. Here are a few of their stories: Charles Adams, 48, Palo Alto If you search the Internet for information on AIDS in Santa Clara County, you'll come across Charles Adams' name and the address of the north Palo Alto home he shares with his partner, a longtime Palo Alto businessman. Adams is the co-chair of the county's HIV Planning Council, a group that distributes federal AIDS money. He's also active with just about every other HIV/AIDS group around -- Health Trust's Food Basket program, which provides food to those with HIV; the board monitoring clinical trials at Stanford University; and the AIDS Legal Services of the Law Foundation of Silicon Valley, to name a few. "Having my partner has enabled me to help," Adams said. "To me, (HIV) is just part of everyday life, and it's easy to talk about. I'm really lucky I'm in such a supportive environment." Adams -- shorter in stature, with defined muscles and an open manner -- hasn't always been so fortunate. Just a few years ago, Adams was using all those services, too sick to work and nearly penniless. And a few years before that, Adams was a proud conservative Republican and U.S. Army officer. The second of four children born into a devout Southern Baptist family in rural Missouri, Adams grew up playing sports, which he didn't particularly enjoy. He dreamed of attending West Point Academy. From a young age he knew he was gay and even tried to tell his parents. In response, they guided him toward religion and more sports, he said. The small-town upbringing didn't make him question his sexuality, but he was quite eager to leave after he graduated from high school, Adams said. "I never gave being gay a second thought. . . . It was just part of life. It wasn't like I flaunted (it). I never drank or did drugs or smoked." Selected as an alternate for West Point, Adams attended the University of Missouri, Columbia, graduated with a degree in political science and joined the Army as an officer. He loved it -- the routine and discipline, the diversity and travel. HIV certainly wasn't on his mind. "We'd all read about something going on (on) the coast. How did that affect me?" Adams said. It did though. Adams got sick in 1983. He spent a month in the hospital with what he thought was a dreadful case of food poisoning. Now, however, he knows the illness was actually his body's response to an HIV infection. Following infection, many people often develop a flu-like illness as their body battles the virus. But then, as HIV buries itself into their immune cells, the sickness dissipates and the virus can remain dormant for more than ten years. Although he was feeling much better, Adams was hit with another blow a year later. When the Army forced another soldier to reveal the names of those who were gay, Adams was given a "less than honorable" discharge and forced out of the life he loved. He returned to Missouri. "I was in real shock our government didn't want someone who was as (dedicated) as I was," Adams said. His political views took a sharp turn to the left. In 1987, HIV tests came out. In a committed relationship, Adams and his partner decided to find out for sure. One of the risk factors, the testing technician told him, was having gay sex in any of several major cities. "I'd had sex in almost all of them. . . . By then I knew -- I knew HIV was possible." Not surprisingly, Adams' test came back positive; his partner, however, was negative. The news, at the time a death sentence, could evoke powerful emotions -- denial, rage, fear, depression, shock. Adams, however, took the news in stride. "I wasn't scared. You have to be responsible for your own choices," he said. Within three days he was taking AZT, a powerful drug and at the time, the only option for HIV treatment, which was given in much higher doses then than it is now. "I was really, really tired. I threw up a lot. It was really nasty," Adams said. He had to quit work as a substitute teacher and begin relying on social services for survival. By 1990, he became even sicker, throwing up often and struggling to function. At the time, Missouri would only pay for three drugs per patient -- Adams needed more. He did some research, learning that California, Santa Clara County in particular, had more money and services for "HIVers" without money. So after a few detours, Adams and his then partner moved to San Jose. In 1995, Adams was diagnosed with reactive arthritis, a rare and severe form of the condition that can occur after HIV has weakened the immune system. Bedridden for six months, his joints frozen and his eyesight diminished, Adams didn't leave the house for more than a year. Adams calls the time "a really weird period." "I've never been the type to get depressed about anything. I never felt sorry for myself. I just thought, 'I just don't want to live, if this is the way it's going to be.'" Then, gradually, life got better. Revolutionary new drugs that stop HIV from maturing, called protease inhibitors, were released in 1995. "Without them, I probably would have died. ... (They) made all the difference in the world," Adams said. He learned to walk again and figured out how to write using fat pens. And he met his current partner. "The reason I liked him so much was he asked, right away, 'What is your status?" Adams said. "There is this big 'Don't ask, don't tell' policy in the gay community." Adams' partner is negative. Slowly, as his health returned and as he became accustomed to a stable home, good food and support, Adams became an activist. "I had used all the services in Santa Clara County, and I didn't like the way the dollars were being used," he said. "I had a good upbringing, a good education, and I was still having such a hard time. . . . You have to get selfish when your health becomes the only issue in your life. Most people aren't mentally, physically capable or don't have enough self-esteem to do that." Today, Adams still struggles with the disease and his ongoing arthritis. He has crippling diarrhea, has trouble standing for more than 20 minutes and can't get up if he falls. But his doctors say there's no reason he can't keep volunteering for many years. "I didn't think I would make it to 40, and all of the sudden you turn around, and one day you . . . have a life." Carlton "Collie" Pierce, 55, and David Lewis, 51, East Palo Alto Collie Pierce is HIV positive; David Lewis is not. Pierce has glasses, a pocked face and a single golden earring. Lewis is imposing, with a trademark mustache and graying hair. Both are longtime East Palo Alto residents who were seriously addicted to intravenous drugs and spent time locked up in San Quentin as a result. And now, they're both working to help others in the grasp of drugs escape. Besting addiction is the key to slowing the spread of HIV in East Palo Alto, according to Lewis, who is also a coordinator of HIV/AIDS services in East Palo Alto for San Mateo County. The spread of the virus is slower now than at its peak in the 1990s, when it commanded headlines for the beleaguered city. Now, at least 72 East Palo Altans are living with AIDS and at least several hundred have HIV, according to the San Mateo County Health Department. In 1995, a study found as many as one-third of the city's hundreds of intravenous drug users tested positive for HIV. Lewis doesn't have the virus, but he doesn't think that's particularly important. "In our community, it doesn't really matter," he said. Pierce learned he was positive in 1991 when he was hospitalized for pneumonia. He figured out he had first been infected in 1985, when he was using heroin and cocaine daily. "Just like so many other people, I didn't know it," Pierce said. "It's so scary that they go on living normal lives ... (sleeping with) multiple partners. ... I was one of those people." "My attitude was it would not and it could not happen to me. When I found out, I went on a death mission." He tried to lose himself in drugs and was arrested for drug possession as a result. His return trip to San Quentin, with HIV, was different, Pierce said. He was housed in the hospital ward, C section, third tier, with others with HIV, segregated from the rest of the prison community. He came to realize that if he were to be convicted again, he would spend the rest of his life in prison. Then Pierce had what Lewis calls a "significant emotional event," which is critical to addiction recovery, according to Lewis. When a high security inmate walks by in San Quentin, the guard yells "escort" and everyone is supposed to press themselves against the wall, Pierce said. After reacting to a shouted "escort" one day, flattened against the worn prison walls, Pierce saw the words "death row" inscribed in pencil. "For me, C section, third tier with HIV positive (people) was like death row. . . . I related to that (inscription)," Pierce said. "That was my last trip to prison. I made a commitment to do anything I could not to return." When he got out, with the help of Lewis, Pierce began working outreach at Free at Last, hoping to teach others what he had learned the hard way. He's been clean and sober for 11 years. "I try to be the best advocate I can. That's why I am so very open. People need to know," Pierce said. "It still goes on. You might not hear about it. But it still goes on; that's why they call it 'the quiet killer.' People are still spreading it; people are still dying." Pierce himself has been fortunate. He hasn't taken an HIV drug since 1999 and feels fine. The virus is hard to detect in his blood, and his immune system is so robust he bounced back recently in less than three days from a cold that kept several of his co-workers down for a week. Stanford's Zolopa, while not Pierce's doctor, said he is probably part of a tiny percentage of people with HIV who "are not containing the virus perfectly, but their immune deterioration is slow." He will probably eventually need medicine, Zolopa said. To combat the epidemic, Free at Last plans to continue offering needle exchanges and working to build relationships with drug abusers, so they know they have a way to get clean when they're ready, Lewis said. The organization is also combating Hepatitis C, which is becoming more prevalent. Hep C is a virus, transmitted with dirty needles, that attacks the liver. Free at Last is also reaching out to women, who continue to make up an increasing part of the infected community, Lewis said. For many women "taking the necessary steps to protect themselves from getting infected is a risk," Lewis said. Stephanie Marshall, 38, Hilmar, Calif. Hilmar is a small town in the Central Valley, a few miles south of Turlock. Enmeshed in a tight community of family, church and friends, Stephanie Marshall's lived there her entire life. Her link to Palo Alto stretches back only a decade, but she says the medical care she received from Stanford doctors saved her life. Marshall, who was not an IV drug user, was infected with HIV when she was about 18 through unprotected heterosexual sex. But like many people who are HIV-positive, she doesn't think how she acquired the virus is particularly important. "We get this illness because of choices we made. ... We have to stand up and take responsibility," Marshall said. "We choose not to use protection. It's nobody's fault but our own. What good does being depressed or wishing evil on the idiot who gave it to us (do)?" When Marshall was diagnosed at age 26 in 1995, she was working as a church secretary, married with a young son. Both her husband and son tested HIV negative. Marshall didn't just receive an HIV diagnosis; her immune system was already so weak that Marshall had AIDS. "I knew nothing about AIDS. We don't have a large homosexual community. I didn't know anybody who had it. It just wasn't in my radar," Marshall said. She quickly learned. "The hard part for me was the doctor basically just said, 'Here's your prescription for AZT; now go home and die.'" Self-described as "sassy," dying wasn't in Marshall's plans. She refused to take AZT, however. Why take a drug that would make her so sick? And as she got sicker, she decided to let everyone in the community know. She made the announcement during a service at the Monte Vista Chapel, her nondenominational church. "The doctors got up and explained how you get it and how you don't get it. The elders laid hands on me," Marshall said. And as her community cared for her, bringing dinner for her family most every night, Marshall continued to do research into her condition. Then she fell in with a group that didn't believe HIV caused AIDS. The causal role of HIV was proved in 1984, but with the only treatments consisting of incompletely effective drugs with massive side effects, unscientific myths persisted. Marshall went to Santa Cruz for a bit to live with an aunt. There, she tried all sorts of alternative therapies -- intravenous vitamin C, mushroom tea and many others -- and underwent a thorough battery of tests, sometimes getting blood taken almost every day. Nothing capable of causing her symptoms, other than HIV, could be found. Marshall began to accept the virus was responsible for her illness. Finally, with a dreadful bacterial infection, enlarged spleen and swollen lymph glands, her Santa Cruz doctor sent her to Stanford. She met Zolopa in 1997. At the time, she weighed only 90 pounds and was wasting away, Zolopa said. He asked why she wasn't taking AZT, Marshall recalled. Marshall explained she didn't want to take such a harmful drug. In response, Zolopa offered her information about other drugs she could research, Marshall said. She hadn't known there were other drugs available. "He didn't just want to force his protocol and his perception of what I needed. (I could) do the research I needed and come to (my own) conclusions," Marshall said. Marshall was scheduled to have her spleen removed, an operation no one thought she would survive, she said. Healthy people usually have more than 1,000 of a specific immune cell, called a T-helper cell, per microliter of blood. Marshall, at her lowest, had only three. An individual has AIDS if his or her T-cell count slips below 200. Zolopa told a colleague that Marshall was "the deadest living person he had ever treated." Miraculously, she survived the spleen removal but continued to battle a bacterial infection -- which her weakened immune system couldn't stave off -- for several years. Now, Marshall drives to Palo Alto only four times a year. Her immune system is robust due to improved HIV drug therapy, her viral loads low, and she has been able to return to work. "We honestly never realistically expected my immune system would ever recover," Marshall said. Marshall's son is grown now, and she was divorced last year. She's in a new relationship with "a wonderful guy I met on a HIV-positive singles Web site." "We understand where we're both coming from. ... We have each others' back." Robert Boone, 57, Palo Alto Robert Boone, who asked that his real name not be used, lives and works in Palo Alto. Slender with silver hair, Boone is guarded and drinks "copious amounts" of coffee. Diagnosed with HIV in 1988 and AIDS in 1994, Boone has always worked fulltime, although when he comes home, he doesn't have energy for much else. Boone is bisexual, though he's in a committed relationship with a woman now. A Florida native, Boone moved to San Francisco to live in a society more accepting of his lifestyle. For about 13 years, Boone said he was very promiscuous. "Did I play safe? Obviously not safe enough," Boone said. "In 1980, I decided it was time to grow up and be respectable," Boone said. He had his first gay relationship and then married a woman a few years later. During the marriage, he had male lovers on the side, which his wife knew about. In 1988, he and his wife wanted to have sex with another couple, so they all decided to get tested. The others were negative; Boone tested positive. "I definitely knew it was in the realm of possibility. Was I expecting it? Probably not," Boone said. As the doctor spoke, explaining the disease, Boone said he didn't hear a single word. The doctor had to discuss the diagnosis with his wife. "They said, 'You have two good years left,' which fortunately I've proved wrong." Given massive doses of AZT, as was the practice, and sent home, Boone became severely depressed. "I did the dumb thing of not trying to get treated for it," Boone said. His marriage started to unravel. "It put a real damper on our sex life, to say the least," Boone said. "I'm just as much at fault. But finally she said, 'I just can't deal with you being sick.'" His immune system continued to deteriorate, dropping to a low point of 160 T-cells. Nonetheless, Boone still worked 40 hours a week. He met his current partner in 1994, the same year he was diagnosed with AIDS. "Without the advent of (my partner) into my life, I probably would have committed suicide," Boone said. This time, he sought out medical treatment for depression. "Things started to level out and then go upwards." Boone jokes that he got his "green card to Palo Alto" in 1995. Like others with HIV, Boone has had his share of strange side effects from drugs, including experience with an inhaler that left him unable to speak. Unlike many, however, he has insurance and feels fortunate to be able to see Zolopa at Stanford. "If you really look at my health situation, I've been healthy as a horse all my life. Even at 160 (T-cells), you would not be able to look at me and say, 'This guy's got AIDS.'" Brown said he has a love/hate relationship with the drugs. "Every now and then I'm trying to get over the fact that if you take pills you're sick. I'm not sick, but I take pills." AIDS is like diabetes now, Boone said, something you can live with. "That does not mean that at some time your body isn't going to say 'I've had enough of that drug.' That's the scary part ... and, and, and 'Is this the beginning of the end?'" Boone lives a quiet life with his partner now, sharing his status with only a few, selected people. "I've given up the men in my life," Boone joked. Boone is slow to preach or judge others' behavior. "I told my mom, 'It doesn't matter how I've got it, the fact is, I've got it.' ... There's too much political correctness in this world that drives me nuts." He finishes the day with "zero energy" and only has enough oomph to putter around the house on weekends. But he, unlike many, many of his friends, is still alive. Source: http://www.paloaltoonline.com/news/show_story.php?id=4800 generic viagra online cheap viagra viagra generic cialis

Tags: hiv, adams, drug, boone, marshall

BREAST CANCER Yahoo News, Mon Apr 24, 3:27 PM ET "NEW YORK (Reuters Health) - African American women, regardless of their socioeconomic status, have a significant and independent risk of having a worse breast outcome compared with white women, according to a combined analysis of several clinical trials." FULL STORY generic cialis viagra cheap cialis generic viagra online

Tags: cancer, breast, generic, women, cialis